Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Equity Average (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Equity Average for 7 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • Quarterly Equity Average rose 46.13% to $1.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 billion through Dec 2025, up 46.13% year-over-year, with the annual reading at $1.2 billion for FY2025, 96.27% up from the prior year.
  • Equity Average for Q4 2025 was $1.3 billion at Kymera Therapeutics, up from $958.9 million in the prior quarter.
  • The five-year high for Equity Average was $1.3 billion in Q4 2025, with the low at $266.7 million in Q2 2021.
  • Average Equity Average over 5 years is $587.7 million, with a median of $473.7 million recorded in 2021.
  • The sharpest move saw Equity Average soared 432.4% in 2021, then fell 21.19% in 2023.
  • Over 5 years, Equity Average stood at $471.4 million in 2021, then rose by 6.39% to $501.5 million in 2022, then decreased by 21.19% to $395.3 million in 2023, then skyrocketed by 118.66% to $864.3 million in 2024, then surged by 46.13% to $1.3 billion in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $1.3 billion, $958.9 million, and $878.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.